Department of Tropical Medicine, Klinikum Wuerzburg Mitte gGmbH, Medical Mission Hospital, Salvatorstrasse 7, 97074, Wuerzburg, Germany.
Medical Mission Institute, Salvatorstrasse 7, 97074, Wuerzburg, Germany.
BMC Infect Dis. 2019 Oct 7;19(1):832. doi: 10.1186/s12879-019-4451-z.
Intestinal schistosomiasis is highly endemic in Tanzania and mass drug administration (MDA) using praziquantel is the mainstay of the control program. However, the MDA program covers only school aged children and does not include neither adult individuals nor other public health measures. The Ijinga schistosomiasis project examines the impact of an intensified treatment protocol with praziquantel MDA in combination with additional public health interventions. It aims to investigate the feasibility of eliminating intestinal schistosomiasis in a highly endemic African setting using an integrated community-based approach. In preparation of this project, we report about baseline data on S.mansoni prevalence, intensity of infection, related hepatosplenic morbidities and their associated factors.
A cross sectional study was conducted among 930 individuals aged 1-95 years living at Ijinga Island, north-western Tanzania in September 2016. Single stool and urine samples were collected from each study participant and processed using Kato Katz (KK) technique and point-of-care Circulating Cathodic (POC-CCA) antigen test for detection of S.mansoni eggs and antigen respectively. Ultrasonographical examination for S.mansoni hepatosplenic morbidities was done to all participants. For statistical analyses Fisher's exact test, chi-square test, student-t-test, ANOVA and linear regression were used where applicable.
Overall based on KK technique and POC-CCA test, 68.9% (95%CI: 65.8-71.8) and 94.5% (95%CI: 92.8-95.8) were infected with S.mansoni. The overall geometrical mean eggs per gram (GMepg) of faeces was 85.7epg (95%CI: 77.5-94.8). A total of 27.1, 31.2 and 51.9% of the study participants had periportal fibrosis (PPF-grade C-F), splenomegaly and hepatomegaly. Risk factors for PPF were being male (aRR = 1.08, 95%CI: 1.02-1.16, P < 0.01), belong to the age group 16-25 years (aRR = 1.23, 95%CI: 105-1.44, P < 0.01), 26-35 years (aRR = 1.42, 95%CI: 1.21-1.67, P < 0.001), 36-45 years (aRR = 1.56, 95%CI:1.31-1.84, P < 0.001) and ≥ 46 years (aRR = 1.64, 95%CI:1.41-1.92, P < 0.001). The length of the left liver lobe was associated with being female (P < 0.03), belong to the age group 1-5 years (P < 0.013), 6-15 years (P < 0.04) and S.mansoni intensity of infection (P < 0.034). Male sex (aRR = 1.15, 95%CI:1.06-1.24, P < 0.001) and belonging to the age groups 16-25 years (aRR = 1.27, 95%CI:1.05-1.54, P < 0.02) or 26-35 years (aRR = 1.32, 95%CI:108-1.61, P < 0.01) were associated with splenomegaly.
Schistosoma mansoni infection and its related morbidities (hepatomegaly, splenomegaly, periportal fibrosis) are common in the study area. Age, sex and intensity of infection were associated with periportal fibrosis. The prevalence of S.mansoni was above 50% in each age group and based on the observed prevalence, we recommend MDA to the entire community.
坦桑尼亚肠道血吸虫病高度流行,采用吡喹酮进行大规模药物治疗(MDA)是控制计划的主要手段。然而,MDA 计划仅覆盖学龄儿童,既不包括成年个体,也不包括其他公共卫生措施。Ijinga 血吸虫病项目研究了在高度流行的非洲环境中,通过强化吡喹酮 MDA 联合其他公共卫生干预措施来消除肠道血吸虫病的可行性。该项目旨在通过基于社区的综合方法,探索消除肠道血吸虫病的可行性。在准备该项目时,我们报告了关于 S.mansoni 流行率、感染强度、相关肝脾疾病及其相关因素的基线数据。
2016 年 9 月,在坦桑尼亚西北部 Ijinga 岛对 930 名年龄在 1-95 岁的个体进行了横断面研究。从每个研究参与者采集一份粪便和尿液样本,并使用加藤厚涂片(KK)技术和即时循环钙黏蛋白(POC-CCA)抗原检测法分别检测 S.mansoni 卵和抗原。对所有参与者进行超声检查以检测 S.mansoni 肝脾疾病。进行统计分析时,使用 Fisher's 确切检验、卡方检验、学生 t 检验、方差分析和线性回归,具体取决于适用情况。
根据加藤厚涂片技术和 POC-CCA 检测法,68.9%(95%CI:65.8-71.8)和 94.5%(95%CI:92.8-95.8)的个体感染了 S.mansoni。粪便的总几何平均卵数(GMepg)为 85.7epg(95%CI:77.5-94.8)。27.1%、31.2%和 51.9%的研究参与者存在门静脉周围纤维化(PPF-C-F)、脾肿大和肝肿大。PPF 的危险因素是男性(ARR=1.08,95%CI:1.02-1.16,P<0.01)、年龄在 16-25 岁(ARR=1.23,95%CI:105-1.44,P<0.01)、26-35 岁(ARR=1.42,95%CI:1.21-1.67,P<0.001)、36-45 岁(ARR=1.56,95%CI:1.31-1.84,P<0.001)和≥46 岁(ARR=1.64,95%CI:1.41-1.92,P<0.001)。左肝叶的长度与性别(P<0.03)、年龄在 1-5 岁(P<0.013)、6-15 岁(P<0.04)和 S.mansoni 感染强度(P<0.034)相关。男性(ARR=1.15,95%CI:1.06-1.24,P<0.001)和年龄在 16-25 岁(ARR=1.27,95%CI:1.05-1.54,P<0.02)或 26-35 岁(ARR=1.32,95%CI:108-1.61,P<0.01)的个体与脾肿大相关。
在研究区域,S.mansoni 感染及其相关疾病(肝肿大、脾肿大、门静脉周围纤维化)很常见。年龄、性别和感染强度与门静脉周围纤维化有关。各年龄组的 S.mansoni 流行率均在 50%以上,根据观察到的流行率,我们建议对整个社区进行 MDA。